| 词条 | Clovis Oncology |
| 释义 |
| traded_as = {{NASDAQ|CLVS}} Russell 2000 Component }}Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology.[1] Clovis was founded in 2009 and is headquartered in Boulder, Colorado.[2] The company is a publicly traded company on NASDAQ under the symbol "CLVS"[3] and is in the NASDAQ Biotechnology Index[4] with several products in its product pipeline.[5] As of December 31, 2017 the company was not profitable and had incurred losses in each year since its inception in April 2009.[6] PipelineIts products include:
RociletinibThe company was developing rociletinib,[7] as a treatment for non-small cell lung cancer.[1][8][9][10] A phase III trial was completed in April 2016[11] and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib).[11] According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.[12] In September 2018, the company and two former executives agreed to a $20M settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials.[13][14] RucaparibRucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.[15]LucitanibLucitanib is a VEGFR inhibitor.[16] it is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.[17]References1. ^1 {{cite web | title=Clovis Oncology: A Winning Or Losing Lottery Ticket? | website=Forbes | date=2015-11-16 | url=https://www.forbes.com/sites/panosmourdoukoutas/2015/11/16/clovis-oncology-a-winning-or-losing-lottery-ticket/ | accessdate=2016-01-04}} 2. ^{{cite web|title=CLVS Profile|url=https://finance.yahoo.com/q/pr?s=CLVS+Profile|website=finance.yahoo.com}} 3. ^{{cite web|title=Clovis Oncology Inc.|url=http://www.marketwatch.com/investing/stock/CLVS|website=www.marketwatch.com|accessdate=4 January 2016}} 4. ^{{cite web|title=Overview NBI|url=https://indexes.nasdaqomx.com/Index/Overview/NBI|website=nasdaq.com|accessdate=4 January 2016}} 5. ^{{cite web|title=Clovis Oncology - Products & Companion Diagnostics |url=http://clovisoncology.com/products-companion-diagnostics |website=Clovisoncology.com |accessdate=4 January 2016 |date=9 March 2015 |deadurl=yes |archiveurl=https://web.archive.org/web/20150309041623/http://clovisoncology.com/products-companion-diagnostics |archivedate=March 9, 2015 }} 6. ^Clovis Oncology, Inc. Form 10-K for the fiscal year ended December 31, 2017. 7. ^{{cite web|last1=Williams|first1=Sean|title=A Festivus for the Invest in Us -- It's Time for the Airing of Grievances|url=http://www.foxbusiness.com/investing/2015/12/23/festivus-for-invest-in-us-it-time-for-airing-grievances/|website=Fox Business|accessdate=4 January 2016|language=en-US|date=23 December 2015}} 8. ^{{cite web|last1=Wallace|first1=Alicia|title=Clovis Oncology stock bludgeoned after delay in cancer drug approval|url=http://www.denverpost.com/business/ci_29124082/clovis-oncology-stock-bludgeoned-after-delay-cancer-drug|website=www.denverpost.com|accessdate=4 January 2016}} 9. ^{{cite web|title=Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing|url=https://www.reuters.com/article/co-clovis-oncology-inc-idUSnBw165513a+100+BSW20151116|archive-url=https://web.archive.org/web/20160305131121/https://www.reuters.com/article/co-clovis-oncology-inc-idUSnBw165513a%2B100%2BBSW20151116|dead-url=yes|archive-date=5 March 2016|website=www.reuters.com|accessdate=4 January 2016|df=}} 10. ^{{cite web | title=FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC | website=OncLive | date=2015-11-16 | url=http://www.onclive.com/web-exclusives/fda-requests-additional-data-for-rociletinib-in-egfr-t790m-mutant-nsclc | accessdate=2016-01-04}} 11. ^1 Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016 12. ^{{cite web |url=http://clovisoncology.com/about-clovis/ |title=About Clovis |access-date=18 November 2016}} 13. ^{{Cite news|url=https://www.reuters.com/article/us-sec-clovis-oncology/clovis-oncology-execs-to-pay-20-million-to-settle-sec-charges-idUSKCN1LY2PD|title=Clovis Oncology, execs to pay $20 million to settle SEC charges|last=|first=|date=2018-09-18|work=Reuters|access-date=2018-09-28|language=en-US}} 14. ^{{Cite web|url=https://www.genengnews.com/gen-news-highlights/clovis-ceo-ex-cfo-agree-to-pay-20m-to-settle-sec-charges/81256252|title=Clovis, CEO, Ex-CFO Agree to Pay $20M+ to Settle SEC Charges {{!}} GEN|website=GEN|access-date=2018-09-28}} 15. ^Rucaparib at Clovis 16. ^Lucitanib at Clovis 17. ^{{cite journal |pmid=25193991 |title=Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors |journal=Annals of Oncology |volume=25 |issue=11 |pages=2244–51 |doi=10.1093/annonc/mdu390 |author=Soria|display-authors=et al |year=2014}} External links
1 : Pharmaceutical companies of the United States |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。